🟢 ROIV is trading 12% up today on a $2.25B Moderna settlement and Q4 earnings

ROIV is trading about 12% up at $31.50 in pre-market after reporting a massive $770.2M pre-tax gain from a $2.25B patent settlement with Moderna.

• The litigation windfall in the fiscal Q4 report lifted GAAP EPS to $0.43 and expanded the company's total cash balance to $4.3B.
• Management provided key pipeline updates, including the discontinuation of batoclimab and a scheduled launch for brepocitinib in September.